Amgen K.K
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
See below for the Latest Amgen K.K News, Analysis, Profit Results, Share Price Information, and Commentary.
NSG biolabs, Amgen partner to leverage biotech ecosystem
NSG biolabs, Amgen partner to leverage biotech ecosystem
It will begin a program to help biotech startups innovate.
Commentary
What matters for Singapore’s AI future is consistency, not brilliance
The AI pilot worked. Now comes the real test
Are Singapore startups’ employee incentive plans still competitive?
Singapore’s small exporters need credit that matches their payment cycle
The hidden realities of succession for next-gen heirs
In Asia, fintech leaders must compete on credibility
F1 on a gravel road: Why AI is still stuck in first gear
Why AI blocklists give Singapore firms a false sense of security
When scale arrives before proof: Singapore’s capital allocation question in Southeast Asia
Rethinking fleet ownership in a changing business landscape